Indivior Pharmaceuticals, Inc. (INDV) Form 8-K — Oct 29, 2026
Indivior reported record Q3 2026 results: total net revenue of $356 million (up 13% YoY), record SUBLOCADE net revenue of $267 million (up 22%), record GAAP net income of $137 million, and record adjusted EBITDA of $211 million, up 76% YoY with a 59% margin. The company reaffirmed its standalone full-year 2026 guidance and said it is on track to close its all-stock merger with Supernus on November 2, 2026. Shareholders approved the deal in October, and a special cash dividend was declared in September contingent on closing. From November 3, 2026, the combined company will operate as Supernus, Inc.
Key figures
- Eps
- 1.12
- Revenue
- 356000000
- Guidance
- FY2026 net revenue $1,295M-$1,365M; SUBLOCADE net revenue $1,010M-$1,050M; non-GAAP opex $430M-$450M; adjusted EBITDA $700M-$740M
- Net Income
- 137000000
- Revenue Yoy
- 13%
- Cash Position
- 332000000
- New ticker
- SUPN effective November 3, 2026
- Merger close date
- November 2, 2026
- Net income margin
- 39%, up 2,500 bps YoY
- Adjusted ebitda q3
- $211 million, up 76% YoY
- Nine month revenue
- $1,016 million, up 15% YoY
- Adjusted ebitda margin
- 59%, up 2,100 bps YoY
- Non gaaap net income q3
- $161 million ($1.32 diluted EPS)
- Sublocade q3 net revenue
- $267 million, up 22% YoY
- Sublocade patients prescribed
- over 583,000 since launch
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.